Compounded vs. brand-name tirzepatide: what you are choosing

Lilly sells tirzepatide under two names. Mounjaro is approved for blood sugar control in type 2 diabetes in adults and children from 10, and to reduce major cardiovascular events in high-risk adults. Zepbound is approved for long-term weight reduction in adults with obesity, or overweight plus a weight-related condition, and for moderate to severe obstructive sleep apnoea with obesity. Both now come as single-dose pens, single-dose vials, multi-dose vials and a four-dose KwikPen.

Tirzepatide acts on two receptors, GLP-1 and GIP. A compounded tirzepatide is a pharmacy preparation prescribed as that drug, typically a vial at a pharmacy-chosen concentration, sometimes with an added ingredient such as glycine. Since the shortage ended, federal policy generally bars a pharmacy from making what FDA calls an "essentially a copy" of an approved product, with limited exceptions described below.

No trial compares compounded tirzepatide with Mounjaro or Zepbound. The outcome evidence belongs to the brands:

• SURMOUNT-1 (NEJM 2022): in adults with obesity and without diabetes, mean weight change over 72 weeks was −15.0% at 5 mg, −19.5% at 10 mg and −20.9% at 15 mg, against −3.1% on placebo.
• SURPASS-CVOT (NEJM): in 13,165 adults with type 2 diabetes and heart disease, major cardiovascular events occurred in 12.2% on tirzepatide against 13.1% on dulaglutide (hazard ratio 0.92), meeting non-inferiority but not superiority.

For the compounded product, the evidence that applies is regulatory. FDA's timeline is:

• 19 December 2024: tirzepatide shortage confirmed resolved.
• 18 February 2025: grace period ends for 503A pharmacies.
• 19 March 2025: grace period ends for 503B outsourcing facilities.
• 6 February 2026: FDA announces steps to restrict GLP-1 ingredients for mass-marketed compounded drugs.

FDA also counted more than 730 adverse event reports tied to compounded tirzepatide as of 31 May 2026. For a patient, the practical meaning is that a legitimate compounded prescription now rests on your prescriber's documented reason, not on a shortage.

Zepbound's label lists nausea, diarrhoea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions and fatigue as reactions in at least 5% of people, clustered around each 2.5 mg step. Its warnings include pancreatitis, gallbladder disease, low blood sugar when combined with insulin or a sulfonylurea, kidney injury from dehydration and aspiration under anaesthesia, plus the boxed warning on thyroid C-cell tumours in rodents.

A compounded tirzepatide carries those risks and a few of its own. Concentrations vary, so a units error can move the dose by a full step. A multi-dose vial should be used within 28 days of the first puncture, per FDA's sterile-vial guidance. And an added ingredient, such as glycine, L-carnitine or vitamin B12, means the product is not the one studied in the label, however small the addition.

Pick the brand whose indication matches your reason. Mounjaro fits type 2 diabetes; Zepbound fits weight management or sleep apnoea with obesity. Either is the straightforward choice when coverage or LillyDirect's self-pay price, from $299 a month for Zepbound 2.5 mg (LillyDirect, checked 28 Sep 2026), puts it in reach.

Compounded tirzepatide now fits a narrower group: people whose prescriber documents a clinical reason the approved product will not work for them, such as a documented allergy to an inactive ingredient in the brand product. That documentation is how a legitimate prescription differs from a copy under FDA policy.

If you go that way, check that the pharmacy is licensed in your state, ask whether it is 503A or 503B, and read the concentration on every label. Treat marketing as a signal too: FDA said in February 2026 that sellers may not call a compounded product generic tirzepatide, the same as Zepbound, or clinically proven, so a seller that does is ignoring the rules you are relying on.